Physician profile
Dan-Arin Silasi
NPI 1154393411
$22,559.56
in general payments reported to CMS, 2019-2025
16 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,481 · 2020: $950 · 2021: $148 · 2022: $9,069 · 2023: $6,708 · 2024: $2,086 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,350 · Food and Beverage: $1,594 · Travel and Lodging: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,350.00 |
| Food and Beverage | $1,594.32 |
| Travel and Lodging | $966.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,438.59 | 2022-2024 | Jemperli, Zejula |
| Immunogen, INC. | $4,284.05 | 2023 | Elahere |
| Intuitive Surgical, INC. | $2,264.94 | 2019-2024 | Da Vinci Surgical System |
| Covidien LP | $1,772.01 | 2019 | |
| Gyrus Acmi, INC. | $950.00 | 2020 | |
| Genmab U.S., INC. | $382.75 | 2022-2024 | Tivdak, Epkinly |
| Astrazeneca Pharmaceuticals LP | $167.87 | 2023 | Lynparza |
| Tempus Ai, INC | $65.23 | 2024 | |
| Merck Sharp & Dohme LLC | $61.73 | 2024-2025 | Keytruda, Lynparza |
| Abbvie INC. | $48.57 | 2024-2025 | |
| Eisai INC. | $32.42 | 2025 | |
| Baxter Healthcare | $31.34 | 2025 | Tisseel |
| Novartis Pharmaceuticals Corporation | $27.15 | 2024 | |
| Myriad Genetic Laboratories, INC. | $18.43 | 2023 | Myrisk |
| Fennec Pharmaceuticals, INC. | $14.48 | 2024 | Pedmark |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan-Arin Silasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.